此应用程序的某些内容目前无法使用。
如果这种情况持续存在,请联系我们反馈与联系
1. (US20170173043) Use of cannabinoids in the treatment of epilepsy

专利局 : 美国
申请号: 15449124 申请日: 03.03.2017
公布号: 20170173043 公布日: 22.06.2017
授权号: 09956184 授权日: 01.05.2018
公布类型: B2
国际专利分类:
A61K 31/05
A61K 31/5513
A 人类生活必需
61
医学或兽医学;卫生学
K
医用、牙科用或梳妆用的制剂
31
含有机有效成分的医药配制品
045
羟基化合物,例如醇类;其盐类,例如醇化物
05
酚类
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
551
having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
5513
1,4-Benzodiazepines, e.g. diazepam
CPC:
A61K 31/05
A61K 31/5513
申请人: GW Pharma Limited
发明人: Geoffrey Guy
Stephen Wright
Alice Mead
Orrin Devinsky
代理人: Fish & Richardson P.C.
优先权数据: 1410771.8 17.06.2014 GB
1506550.1 17.04.2015 GB
标题: (EN) Use of cannabinoids in the treatment of epilepsy
摘要:
(EN)

The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).


也发表为:
AU2015275886AU2015275887CA2952858CA2952994JP2017519758JP2017524672
US20150359755US20150359756US20170172939US20170172940US20170173044US20170181982
US20170246121US20180338931